Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

4.58
Delayed Data
As of Dec 07
 +0.0182 / +0.40%
Today’s Change
3.50
Today|||52-Week Range
10.89
-28.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$344.9M

Company Description

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
Level 38
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:
(212) 880-2060

Employees

Shareholders

Mutual fund holders2.63%
Other institutional0.61%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, MD & Executive Director
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Michael SchusterHead-Pharma Partnering
Jonathan Richard SymondsHead-Corporate Finance & Strategy